Low‐grade serous ovarian carcinoma: A comprehensive literature review

Abstract

Background Low‐grade serous ovarian carcinoma (LGSOC) is a unique entity with clinical and molecular characteristics distinct from high‐grade serous ovarian carcinoma (HGSOC). To date the majority of research has focused on the more common HGSOC, with treatment recommendations often extrapolated to LGSOC. Women with LGSOC are typically diagnosed younger and have indolent and relatively chemoresistant disease. Recently there have been major research advances in LGSOC. Aims This systematic review describes the epidemiological, clinical and molecular characteristics of LGSOC, with advances in research and novel treatment options also discussed. Materials and Methods A 10‐year comprehensive systematic review of peer‐reviewed literature was conducted, with a total of 132 abstracts read, 89 articles reviewed and 49 included in this review. Results This review highlights the clinical and molecular features of LGSOC, current and traditional treatment options and areas of current research into targeted agents. Conclusions Our growing knowledge about LGSOC as a distinct clinical and molecular entity from HGSOC has led to the investigation of more targeted and tailored therapies as their clinical course, optimal management and therapeutic targets differ. There is a need for ongoing collaborative research to provide better treatment options for these patients.

Prognosis role of epitelial-mezenchimal transformation markers and surface stem tumor cells in the reccurence of serous low grade ovarian carcinomas

“…Clinical data of our study show that recurrence of LGSC occur in patients with stage III-IV disease by FIGO (p=0.0051) and were not detected in stage I, although according to the literature LGSC have an indolent course, less often diagnosed on advanced stages and have more favourable prognosis [7,14]. The relationship is confirmed by a direct correlation between disease stage and reoccur (p=0.00039).…”

“…Type I is represented by serous carcinoma of low malignancy (LGSC), and type II -serous carcinoma of high malignancy (HGSC). [7] Although LGSC accounts for only 5 % of all SOCs, and the leading role is played by HGSC [8], the study of molecular genetic and biological features of LGSC is extremely important for the ability to predict tumor behavior and selection of targeted therapy.…”

Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis

“…Our result that BRCA1/2 PVs were detected in patients having endometrioid OC, clear cell OC, LGSOC, or mucinous OCs does not fit within the classical hypothesis of the origin of these carcinomas. Endometrioid and clear cell OCs are thought to develop from endometriosis [54], whereas LGSOCs are thought to develop from cystadenomas or tubal lesions [55], and mucinous OCs are thought to develop from Brenner tumors or teratomas [56]. The development of non-HGSOC in women with BRCA1/2 PV suggests another carcinogenic pathway, but precursor lesions of these histological subtypes are not known to be more frequently observed during prophylactic RRSO in women with BRCA1/2 PV.…”

Hubungan Ekspresi PD-L1 dengan Derajat Diferensiasi dan Densitas Til di Stroma pada Karsinoma Ovarium Serosum

“…Insiden karsinoma ovarium ini terbanyak pada usia perimenopause yang dihubungkan dengan peran hormonal dalam patogenesis. 16 Proporsi umur terbanyak pada penelitian ini pada dekade ke-6 sebanyak 35,6% selanjutnya dekade ke-5 sebanyak 33,3%. Sedikit berbeda dengan hasil penelitian Oktari dkk.…”